Opportunities in the SMA market include leveraging the launch of new myostatin inhibitors, expanding Zolgensma formulations to increase patient eligibility, and capitalizing on cheap nusinersen ...
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...
On 25 November 2025, Novartis Pharmaceuticals conducted a study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with ...
SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of ...
-- Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community Mary Fiance, National Vice ...
Novartis’ Itvisma (onasemnogene) has been approved by the US FDA to treat spinal muscular atrophy (SMA) in children aged two ...
Far from any battlefield, North Texas scientists are testing a familiar nutrient they hope can help regrow soldiers' damaged ...
Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studiesOne-time dose of Itvisma replaces ...
Jeremy Bray, 29, lives with Spinal Muscular Atrophy, a neurodegenerative disorder that causes the loss of motor neurons and ...
The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...
Basel: Novartis has received approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogene ...
The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback